ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy

作者：Smith, Stephanie; Su, Dan; de la Longrais, Irene A. Rigault; Schwartz, Peter; Puopolo, Manuela; Rutherford, Thomas J.; Mor, Gil; Yu, Herbert^*; Katsaros, Dionyssios

来源：Journal of Clinical Oncology, 2007, 25(33): 5172-5179.

DOI：10.1200/JCO.2007.11.8547

• CELL LUNG-CANCER
• COMPLEMENTATION GROUP-1 POLYMORPHISM
• NUCLEOTIDE EXCISION-REPAIR
• COMBINATION CHEMOTHERAPY
• SILENT MUTATIONS
• CISPLATIN
• EXPRESSION
• SURVIVAL
• ASSOCIATION
• RESISTANT

Purpose To investigate the effect of excision repair cross-complementation group 1 (ERCC1) on treatment response and survival of patients treated with platinum chemotherapy with or without paclitaxel.
Patients and Methods Tumor samples from epithelial ovarian cancer patients were evaluated for ERCC1 mRNA expression and a single nucleotide polymorphism at codon 118 (C > T). Of 178 patients treated with postoperative platinum-based chemotherapy, 75 were also given paclitaxel. For all of these patients, ERCC1 expression and genotype were analyzed for associations with treatment response and survival.
Results Among the 103 patients treated with platinum without paclitaxel, the C/C genotype, compared with C/T and T/T, was associated with greater risk of disease progression and death (hazard ratio [HR], 1.95, P = .051; HR, 2.01, P = .033, respectively); high levels of ERCC1 mRNA, compared with low levels, were associated with greater risk of disease progression (HR, 2.41; P = .014). Similarly, when the ERCC1 data were combined, patients with the C/C genotype and high ERCC1 expression had greater risk for disease progression (HR, 3.73; P = .003) compared with those with low expression and non-C/C genotype. However, for the 75 patients treated with platinum plus paclitaxel, the C/C genotype and high ERCC1 expression were not associated with poor prognosis, suggesting that paclitaxel may help to alleviate ERCC1-related platinum resistance.
Conclusion Ovarian cancer patients with high ERCC1 expression or the C/C genotype at codon 118 may benefit from the combination of platinum and paclitaxel, while those with low ERCC1 expression or the C/T or T/T genotype may respond well to platinum without paclitaxel.

• 出版日期2007-11-20
• 单位浙江省肿瘤医院